कंपनी का अवलोकन
High Tide Inc. operates primarily within the healthcare sector, specifically serving the pharmaceutical retail industry by engaging in the cannabis retail business across Canada, the United States, and international markets. The company executes its operations through three distinct segments including bricks and mortar retail locations, e-commerce platforms, and medical cannabis distribution channels. In terms of scale, the enterprise carries a market capitalization of $200.41M while reporting an annual revenue of $629.85M over the trailing twelve-month period. The organization maintains a workforce of 1,832 employees, indicating a mid-sized operational footprint within the specialized cannabis industry. These valuation and revenue figures suggest that High Tide Inc. has established a significant presence in a regulated market, though its relatively modest market cap relative to its revenue stream of nearly $630 million points to a specific valuation dynamic common in sectors with high growth potential but currently suppressed earnings due to regulatory or operational costs.
वित्तीय स्वास्थ्य
The company reported a revenue of $629.85M and an EBITDA of $29.05M, yet it recorded a net income of -$46,734,000 for the trailing twelve months. This substantial gap between positive EBITDA and negative net income reveals a significant impact from non-operating expenses, likely driven by interest costs associated with its debt obligations or other non-recurring items that erode bottom-line profitability. Despite the net loss, the business generated free cash flow of $7.70M, which indicates that the core operations are capable of producing cash sufficient to cover operational needs and potentially fund limited capital expenditures. The company holds a cash balance of $37.35M against total debt of $112.50M, resulting in a debt-to-equity ratio of 110.31 which characterizes the balance sheet as highly leveraged rather than conservative. However, the current ratio stands at 1.43, suggesting that the firm possesses adequate short-term liquidity to meet its immediate obligations without immediate distress. Furthermore, the return on equity is -39.7% while the return on assets is 3.9%, illustrating a complex financial picture where asset utilization is marginally positive but equity value is being diluted by the reported losses. These return metrics collectively reveal that management is currently prioritizing growth and market expansion over immediate profitability, a strategy that impacts shareholder equity but may be necessary for long-term survival in a developing industry.
मूल्यांकन आकलन
The valuation metrics present a notable divergence between historical and future expectations, as the trailing twelve-month P/E ratio is listed as N/A due to negative earnings, whereas the forward P/E is calculated at 16.11. This difference implies that the market anticipates a significant turnaround in earnings trajectory over the next twelve months, expecting the company to move from a loss position to profitability. The price-to-book ratio is 3.16, indicating that the market values the company at more than three times its net asset value, which suggests a premium assigned to its intangible assets, brand value, or growth prospects within the pharmaceutical retail space. Alternative valuation measures further contextualize the stock, with a price-to-sales ratio of 0.32 and an EV/EBITDA of 9.95, suggesting that the stock is priced at a discount relative to its sales volume while maintaining a reasonable multiple of its earnings before interest, taxes, depreciation, and amortization. Regarding price volatility, the 52-week high is $4.05 and the 52-week low is $1.66, placing the current trading range within a wide band that reflects significant investor sentiment shifts. The beta value is 1.02, meaning the stock's price volatility is slightly higher than the broader market average, moving in tandem with general market fluctuations but with a slight upward bias in sensitivity.
Growth & Income
High Tide Inc. demonstrated a robust revenue growth rate of 25.2% year-over-year, while earnings growth is N/A due to the current net loss position. This dynamic implies that top-line expansion is outpacing any potential bottom-line improvement, as the company is still absorbing the costs associated with scaling its retail and distribution network. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, confirming that it reinvests all available earnings back into the business rather than distributing cash to shareholders. This reinvestment strategy is typical for companies in the early or growth stages of a lifecycle, where capital is required to fund inventory, expand store counts, and navigate regulatory compliance costs. Consequently, the overall growth and income profile is characterized by aggressive expansion driven by revenue growth rather than income generation or shareholder distributions, positioning the stock as a pure-play growth vehicle within the Canadian and international cannabis sectors.